Independent Study Conducted At Boston Children's Hospital, Harvard Medical School, Shows Potential Utility Of Jaguar Health's Crofelemer For Treatment Of MVID, A Rare Childhood Disease
Portfolio Pulse from Benzinga Newsdesk
An independent study conducted at Boston Children's Hospital and Harvard Medical School has shown potential utility of Jaguar Health's drug, Crofelemer, for the treatment of MVID, a rare childhood disease. Currently, there are no approved drug treatments for MVID. Crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for MVID, and Jaguar Health's Investigational New Drug application for crofelemer for treatment of MVID is now activated by the FDA.
October 19, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jaguar Health's drug, Crofelemer, shows potential for treating MVID, a rare childhood disease. The FDA has activated the company's Investigational New Drug application for the treatment.
The news is directly related to Jaguar Health and its drug, Crofelemer. The positive results from the independent study and the activation of the Investigational New Drug application by the FDA could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100